{
 "context": "The following article called 'GSK to profile new class of antibiotic at Nov. 3 investor day' was published on 2015-10-22. The body of the article is as follows:\n    \nTip : Use comma (,) to separate multiple quotes. Learn more... \nFri, Oct 23, 2015, 07:05 BST - UK Markets open in 55 mins. GSK to profile new class of antibiotic at Nov. 3 investor day Reuters - UK Focus \u2013 9 hours ago 20.86 +0.71 \nLONDON, Oct (HKSE: 3366-OL.HK - news ) 22 (Reuters) - British pharmaceutical company GlaxoSmithKline (Other OTC: GLAXF - news ) will profile its drug development pipeline, including a new class of antibiotic, on Nov. 3, its chief executive said on Thursday. \nThe event in New York - the company's first investor day centred on drug development for more than a decade - will profile medicines from a pipeline that is 80 percent first-in-class, Andrew Witty said in a public interview at the Chatham House think-tank in London. \nIt (Other OTC: ITGL - news ) will include an update on its Type 2 topoisomerase inhibitor drug candidate, which is in the Phase II stage of development, according to Witty. \nHe said that only two new classes of antibiotics - drugs which treat bacterial infections - had been discovered in the past 40 years. \"We have a third one,\" he said. \n(Reporting by Paul Sandle; Editing by Mark Heinrich)\n\n    The day before the article was published, the stock price of GlaxoSmithKline PLC was 28.980670928955078 and the day after the article was published, the stock price of GlaxoSmithKline PLC was ",
 "expected": "29.86725616455078",
 "date": "2015-10-22",
 "ticker": "GSK",
 "company": "GlaxoSmithKline PLC"
}